HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial M & A OTC Drugs

Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt

  • News

Executive Summary

Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.

You may also be interested in...



Consumer Health Changes ‘At Speed Of Instagram’ Drive J&J’s Decision On Separating Businesses

J&J provided color on plans for standalone consumer health business during a business overview with analysts. Multiple separation pathways are being considered.

Bausch + Lomb Second On Bausch Health IPO Card

Canadian firm plans to separate Solta first, with an IPO in December or January, and at least 30 days later offer shares in Bausch + Lomb. Order of IPOs could change, though.

Bausch Health Lubricates Bausch + Lomb's Pending Separation With Hydration Eye Drops Launch

Biotrue Hydration Boost contains glyercrin, available in the US as an ophthalmic remedy under an FDA OTC monograph. Launch is latest addition to Baush + Lomb consumer portfolio as Bausch Health prepares to make it a standalone firm.

Table

View full table

Topics

Related Companies

Tags:
Commercial M & A OTC Drugs
UsernamePublicRestriction

Register

RS151957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By